

PRESS RELEASE

Date 31 January 2023
Contact Investor Relations: Julian Fiessinger, Head of Investor Relations & Corporate Finance
Media Relations: Julian Stressig, Senior Corporate Communications Manager
Topic Verfora acquires Padma Ltd.

Verfora continues to expand its complementary medicine portfolio

The Galenica subsidiary Verfora will acquire 100% of Padma Ltd. at the end of January. Padma specialises in the manufacture and distribution of herbal formulations derived from Tibetan medicine. With the acquisition, Verfora is expanding its complementary medicine portfolio and expanding its range of reimbursable medicines.

Padma Ltd. has been a manufacturer of herbal formulations from Tibetan medicine since 1969 and has its own production facility in Wetzikon (ZH), where the company's headquarters are also located. The Tibetan constitutional teachings include behavioural tips for a healthy lifestyle and recommend the use of carefully compounded natural herbal formulations for specific conditions. The main products are Padma 28N and Padmed Circosan N, which are the market leaders in Switzerland for the treatment of mild circulatory disorders. Whereas Padma 28N is freely available on the market as an OTC preparation, Padmed Circosan N is on the speciality list and can be billed through health insurance funds if prescribed by doctors. Other products include Padma Digestin Plus for balanced digestion and Padma Nervoben, which supports the normal functioning of the nervous system.

Ideal addition to the product portfolio with further growth potential

The acquisition is an ideal addition to Verfora's complementary medicine product range. In addition, the Padma 28 N and Padmed Circosan N products will give Verfora a market-leading position in the treatment of mild circulatory disorders, an indication that Verfora has not previously covered. Thanks to the Verfora medical field sales force, the potential of Padma products can be exploited even better in the future.

Padma Ltd. will be managed at Galenica as an independent Business Unit in the Products & Marketing area. All 39 employees at the headquarters in Wetzikon will be taken on. Total market sales at retail prices in Switzerland of around CHF 10 million account for around 70% of Padma Ltd.'s total sales. The most important export markets are Germany and Austria. Both parties have agreed not to disclose the purchase price.

Date 31 January 2023
Page 2/2
Topic Verfora acquires Padma Ltd.

Dates for the diary

7 March 2023: Publication of the 2022 results for the Galenica Group
3 May 2023: Annual General Meeting of Galenica Ltd.
8 August 2023: Publication of the half-year results for 2023

For further information, please contact:

Media Relations:

Julian Stressig
Senior Corporate Communications Manager
Tel. +41 58 852 85 17
E-mail: media@galenica.com

Investor Relations:

Julian Fiessinger
Head of Investor Relations
Tel. +41 58 852 85 31
E-mail: investors@galenica.com

Galenica is the leading fully integrated healthcare provider in Switzerland. With over 500 own, joint venture and independent partner pharmacies, Galenica operates the largest network of pharmacies in Switzerland. In addition, Galenica develops and offers well-known own consumer brands and products and exclusive brands and products from business partners, as well as offering a variety of on-site health services and tests for customers. Galenica is also the leading provider of both pre-wholesale and wholesale distribution services and database services in the Swiss healthcare market. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information concerning Galenica can be found at www.galenica.com.

Padma Ltd. has been the only manufacturer worldwide of Swiss-quality herbal formulations based on Tibetan medicine and Tibetan constitutional teachings since 1969. All Padma herbal compositions are produced exclusively in Switzerland and are based on collections of centuries-old traditional formulations. To this day, the fusion of Tibetan traditions with the modern production of formulations from plants and minerals in accordance with Western standards remains pioneering. The secret of formulations from Tibetan medicine is the holistic approach taken by Padma products. Padma Ltd. therefore sees itself as a pioneer of the holistic approach. More than half a century of practical experience and scientific studies enable a synthesis of modern research and centuries-old tradition. Additional information about Padma Ltd. can be found at www.padma.ch.